Detection of Overlooked Rare EGFR Mutations in Non‐small Cell Lung Cancer Using Multigene Testing
Thoracic Cancer · 2025-02 · 16 (3)
DOI: 10.1111/1759-7714.70007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thoracic Cancer, online erschienen am 13.02.2025. Verfasst von Naoki Shiraishi und 18 weiteren Autor:innen. Beteiligte Einrichtung: Genome Medical Center, Kindai University Hospital, Osaka, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Mutation, Genetic Testing. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Recognizing rare molecular variants of driver mutations poses a challenge in precision oncology, particularly for treatment of non‐small cell lung cancer (NSCLC). In this study, we aimed to determine whether Oncomine Dx Target Test Multi‐CDx System (ODxTT), the most widely used genetic test for NSCLC in Japan, potentially overlooks druggable EGFR mutations. Materials and Methods Among 418 patients who underwent molecular testing using ODxTT at our hospital, 267 were diagnosed with adenocarcinoma. No mutations were reported in 82 of these cases. For these 82 cases, we searched for EGFR mutations in exons 18–21 by examining the binary alignment map file. Once a mutation was identified, its pathological significance was evaluated using the ClinVar database to determine whether ODxTT had overlooked any actionable EGFR mutations.
Results
Mutations in EGFR exons 19 and 18 were identified in six and four cases, respectively. Three, six, and none of these variants were detectable using the Cobas EGFR Mutation Test v2, Lung Cancer Compact Panel, and Amoy Dx, respectively. Of the 10 patients, five were subsequently treated with EGFR TKI; three showed partial response, one had stable disease, and one had progressive disease.
Conclusions
ODxTT failed to identify 10 actionable EGFR mutations, accounting for 12.2% (10/82) of the cases initially reported as not carrying actionable mutations. Therefore, comprehensive genomic profiling should be actively performed early in cases with high clinical suspicion of EGFR mutations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Genome Medical Center, Kindai University Hospital, Osaka, Japan.
- Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan.
- Department of Genome Biology, Kindai University Faculty of Medicine, Osaka, Japan.
- Department of Medical Oncology, Kishiwada City Hospital, Osaka, Japan.
- Clinical Research Center, Kindai University Hospital, Osaka, Japan.
- Izumi City General Hospital, Osaka, Japan.
ORCID-Profile: Takayuki Takahama
Zitieren
APA
Shiraishi, N., Takahama, T., Sakai, K., Tanaka, K., Nakagawa, Y., Kanemura, H., Nakayama, T., Kawanaka, Y., Kurosaki, T., Suzuki, S., Iwasa, T., Tanizaki, J., Inagaki, C., Yonesaka, K., Fukuoka, K., Mitsudomi, T., Nishio, K., Hayashi, H., & Nakagawa, K. (2025). Detection of Overlooked Rare EGFR Mutations in Non‐small Cell Lung Cancer Using Multigene Testing. Thoracic Cancer, 16(3). https://doi.org/10.1111/1759-7714.70007
Vancouver
Shiraishi N, Takahama T, Sakai K, Tanaka K, Nakagawa Y, Kanemura H, et al. Detection of Overlooked Rare EGFR Mutations in Non‐small Cell Lung Cancer Using Multigene Testing. Thoracic Cancer. 2025;16(3). doi:10.1111/1759-7714.70007
BibTeX
@article{Shiraishi2025,
author = {Shiraishi, Naoki and Takahama, Takayuki and Sakai, Kazuko and Tanaka, Kaoru and Nakagawa, Yuzuki and Kanemura, Hiroaki and Nakayama, Tomohiro and Kawanaka, Yusuke and Kurosaki, Takashi and Suzuki, Shinichiro and Iwasa, Tsutomu and Tanizaki, Junko and Inagaki, Chiaki and Yonesaka, Kimio and Fukuoka, Kazuya and Mitsudomi, Tetsuya and Nishio, Kazuto and Hayashi, Hidetoshi and Nakagawa, Kazuhiko},
title = {Detection of Overlooked Rare EGFR Mutations in Non‐small Cell Lung Cancer Using Multigene Testing},
journal = {Thoracic Cancer},
year = {2025},
volume = {16},
number = {3},
doi = {10.1111/1759-7714.70007}
}
EUVIMED